ACS Nano:医疗纳米粒子:肺癌的局部治疗

2015-03-09 崔倩译 MedSci原创

纳米粒子可以作为对抗肺癌药物的载体。NIM(纳米系统倡议者慕尼黑)卓越集群的联合项目,来自亥姆霍兹慕尼黑中心(HMGU)和路德维希 - 马克西米利安大学(LMU)在慕尼黑的科学家已经开发了一种纳米粒子可作为载体的药物,人类和小鼠的肺部肿瘤部位有选择地释放药物。在 “ACS Nano” 杂志中,科学家报告说,这种做法使目前的抗癌药物在肺癌肿瘤组织的有效性显著增加。 纳米颗粒是极其微小的粒子,可将其

纳米粒子可以作为对抗肺癌药物的载体。NIM(纳米系统倡议者慕尼黑)卓越集群的联合项目,来自亥姆霍兹慕尼黑中心(HMGU)和路德维希 - 马克西米利安大学(LMU)在慕尼黑的科学家已经开发了一种纳米粒子可作为载体的药物,人类和小鼠的肺部肿瘤部位有选择地释放药物。在 “ACS Nano” 杂志中,科学家报告说,这种做法使目前的抗癌药物在肺癌肿瘤组织的有效性显著增加。

纳米颗粒是极其微小的粒子,可将其进行修饰用在医疗领域中。例如,纳米粒子可以被设计为能够运送药品的具体病变部位而不影响健康的身体部分。

选择性药物输送首次在人体组织验证。

慕尼黑科学家研制的纳米载体,只有在肺肿瘤区域释放药物。由Silke Meiners领导的研究小组,来自综合肺病中心(HMGU)的Oliver Eickelberg和Sabine van Rijt,与Thomas Bein领导的化学部(LMU)的同事(LMU),第一次发现纳米颗粒对人肺肿瘤组织的选择性药物释放。

肿瘤特异性蛋白被用来从纳米载体释放药物。

在肺肿瘤组织中含有高浓度的某些蛋白酶,它们是分解和切割特定蛋白质的酶。科学家利用了这些特点来修饰纳米载体,加上了一个保护层,这个蛋白酶只有这些蛋白酶可以分解,然后释放出药物。蛋白酶浓度在健康的肺组织太低以至于不能切割该保护层,所以药物在纳米粒子中被保护。

“使用这些纳米载体,我们可以非常有选择地释放药物,如化疗药物专门针对肺肿瘤,”报告研究组组长Meiners说。“我们观察到,在肿瘤组织中的药物的有效性是药物自行使用的10至25倍。同时,这种方法还使得有可能降低药物的总剂量,从而减少不良影响“。
进一步的研究将是检测体内的纳米载体的安全性,以及用肺肿瘤小鼠模型验证的临床疗效。

原始出处

Sabine H. van Rijt, Deniz A. Bölükbas, Christian Argyo, Stefan Datz, Michael Lindner, Oliver Eickelberg, Melanie Königshoff, Thomas Bein, Silke Meiners.Protease-Mediated Release of Chemotherapeutics from Mesoporous Silica Nanoparticles toex VivoHuman and Mouse Lung Tumors. ACS Nano, 2015;

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=23771, encodeId=64f323e71ce, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sat May 16 20:03:00 CST 2015, time=2015-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1772925, encodeId=8f521e7292531, content=<a href='/topic/show?id=89f3e742947' target=_blank style='color:#2F92EE;'>#纳米粒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77429, encryptionId=89f3e742947, topicName=纳米粒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8ae38449394, createdName=zjubiostat, createdTime=Mon Jun 22 13:04:00 CST 2015, time=2015-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18332, encodeId=302e18332e1, content=不知道其他肿瘤是否也能利用相似的机理制作出相应的纳米材料, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f12104305, createdName=hjj0000, createdTime=Sun Mar 15 09:20:00 CST 2015, time=2015-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279082, encodeId=e2f012e9082b0, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Wed Mar 11 01:04:00 CST 2015, time=2015-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405672, encodeId=498814056e2d0, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Wed Mar 11 01:04:00 CST 2015, time=2015-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425809, encodeId=ff451425809c0, content=<a href='/topic/show?id=a1e44e62210' target=_blank style='color:#2F92EE;'>#局部治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47622, encryptionId=a1e44e62210, topicName=局部治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1d3994789, createdName=venlin, createdTime=Wed Mar 11 01:04:00 CST 2015, time=2015-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580608, encodeId=93bf1580608d0, content=<a href='/topic/show?id=d4c6e7430be' target=_blank style='color:#2F92EE;'>#纳米粒子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77430, encryptionId=d4c6e7430be, topicName=纳米粒子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eedc16636878, createdName=ms920641618706883, createdTime=Wed Mar 11 01:04:00 CST 2015, time=2015-03-11, status=1, ipAttribution=)]
    2015-05-16 ljjj1053

    很不错学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=23771, encodeId=64f323e71ce, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sat May 16 20:03:00 CST 2015, time=2015-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1772925, encodeId=8f521e7292531, content=<a href='/topic/show?id=89f3e742947' target=_blank style='color:#2F92EE;'>#纳米粒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77429, encryptionId=89f3e742947, topicName=纳米粒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8ae38449394, createdName=zjubiostat, createdTime=Mon Jun 22 13:04:00 CST 2015, time=2015-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18332, encodeId=302e18332e1, content=不知道其他肿瘤是否也能利用相似的机理制作出相应的纳米材料, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f12104305, createdName=hjj0000, createdTime=Sun Mar 15 09:20:00 CST 2015, time=2015-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279082, encodeId=e2f012e9082b0, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Wed Mar 11 01:04:00 CST 2015, time=2015-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405672, encodeId=498814056e2d0, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Wed Mar 11 01:04:00 CST 2015, time=2015-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425809, encodeId=ff451425809c0, content=<a href='/topic/show?id=a1e44e62210' target=_blank style='color:#2F92EE;'>#局部治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47622, encryptionId=a1e44e62210, topicName=局部治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1d3994789, createdName=venlin, createdTime=Wed Mar 11 01:04:00 CST 2015, time=2015-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580608, encodeId=93bf1580608d0, content=<a href='/topic/show?id=d4c6e7430be' target=_blank style='color:#2F92EE;'>#纳米粒子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77430, encryptionId=d4c6e7430be, topicName=纳米粒子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eedc16636878, createdName=ms920641618706883, createdTime=Wed Mar 11 01:04:00 CST 2015, time=2015-03-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=23771, encodeId=64f323e71ce, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sat May 16 20:03:00 CST 2015, time=2015-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1772925, encodeId=8f521e7292531, content=<a href='/topic/show?id=89f3e742947' target=_blank style='color:#2F92EE;'>#纳米粒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77429, encryptionId=89f3e742947, topicName=纳米粒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8ae38449394, createdName=zjubiostat, createdTime=Mon Jun 22 13:04:00 CST 2015, time=2015-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18332, encodeId=302e18332e1, content=不知道其他肿瘤是否也能利用相似的机理制作出相应的纳米材料, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f12104305, createdName=hjj0000, createdTime=Sun Mar 15 09:20:00 CST 2015, time=2015-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279082, encodeId=e2f012e9082b0, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Wed Mar 11 01:04:00 CST 2015, time=2015-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405672, encodeId=498814056e2d0, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Wed Mar 11 01:04:00 CST 2015, time=2015-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425809, encodeId=ff451425809c0, content=<a href='/topic/show?id=a1e44e62210' target=_blank style='color:#2F92EE;'>#局部治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47622, encryptionId=a1e44e62210, topicName=局部治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1d3994789, createdName=venlin, createdTime=Wed Mar 11 01:04:00 CST 2015, time=2015-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580608, encodeId=93bf1580608d0, content=<a href='/topic/show?id=d4c6e7430be' target=_blank style='color:#2F92EE;'>#纳米粒子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77430, encryptionId=d4c6e7430be, topicName=纳米粒子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eedc16636878, createdName=ms920641618706883, createdTime=Wed Mar 11 01:04:00 CST 2015, time=2015-03-11, status=1, ipAttribution=)]
    2015-03-15 hjj0000

    不知道其他肿瘤是否也能利用相似的机理制作出相应的纳米材料

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=23771, encodeId=64f323e71ce, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sat May 16 20:03:00 CST 2015, time=2015-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1772925, encodeId=8f521e7292531, content=<a href='/topic/show?id=89f3e742947' target=_blank style='color:#2F92EE;'>#纳米粒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77429, encryptionId=89f3e742947, topicName=纳米粒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8ae38449394, createdName=zjubiostat, createdTime=Mon Jun 22 13:04:00 CST 2015, time=2015-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18332, encodeId=302e18332e1, content=不知道其他肿瘤是否也能利用相似的机理制作出相应的纳米材料, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f12104305, createdName=hjj0000, createdTime=Sun Mar 15 09:20:00 CST 2015, time=2015-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279082, encodeId=e2f012e9082b0, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Wed Mar 11 01:04:00 CST 2015, time=2015-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405672, encodeId=498814056e2d0, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Wed Mar 11 01:04:00 CST 2015, time=2015-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425809, encodeId=ff451425809c0, content=<a href='/topic/show?id=a1e44e62210' target=_blank style='color:#2F92EE;'>#局部治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47622, encryptionId=a1e44e62210, topicName=局部治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1d3994789, createdName=venlin, createdTime=Wed Mar 11 01:04:00 CST 2015, time=2015-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580608, encodeId=93bf1580608d0, content=<a href='/topic/show?id=d4c6e7430be' target=_blank style='color:#2F92EE;'>#纳米粒子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77430, encryptionId=d4c6e7430be, topicName=纳米粒子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eedc16636878, createdName=ms920641618706883, createdTime=Wed Mar 11 01:04:00 CST 2015, time=2015-03-11, status=1, ipAttribution=)]
    2015-03-11 yaanren
  5. [GetPortalCommentsPageByObjectIdResponse(id=23771, encodeId=64f323e71ce, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sat May 16 20:03:00 CST 2015, time=2015-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1772925, encodeId=8f521e7292531, content=<a href='/topic/show?id=89f3e742947' target=_blank style='color:#2F92EE;'>#纳米粒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77429, encryptionId=89f3e742947, topicName=纳米粒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8ae38449394, createdName=zjubiostat, createdTime=Mon Jun 22 13:04:00 CST 2015, time=2015-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18332, encodeId=302e18332e1, content=不知道其他肿瘤是否也能利用相似的机理制作出相应的纳米材料, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f12104305, createdName=hjj0000, createdTime=Sun Mar 15 09:20:00 CST 2015, time=2015-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279082, encodeId=e2f012e9082b0, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Wed Mar 11 01:04:00 CST 2015, time=2015-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405672, encodeId=498814056e2d0, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Wed Mar 11 01:04:00 CST 2015, time=2015-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425809, encodeId=ff451425809c0, content=<a href='/topic/show?id=a1e44e62210' target=_blank style='color:#2F92EE;'>#局部治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47622, encryptionId=a1e44e62210, topicName=局部治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1d3994789, createdName=venlin, createdTime=Wed Mar 11 01:04:00 CST 2015, time=2015-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580608, encodeId=93bf1580608d0, content=<a href='/topic/show?id=d4c6e7430be' target=_blank style='color:#2F92EE;'>#纳米粒子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77430, encryptionId=d4c6e7430be, topicName=纳米粒子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eedc16636878, createdName=ms920641618706883, createdTime=Wed Mar 11 01:04:00 CST 2015, time=2015-03-11, status=1, ipAttribution=)]
    2015-03-11 chg122
  6. [GetPortalCommentsPageByObjectIdResponse(id=23771, encodeId=64f323e71ce, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sat May 16 20:03:00 CST 2015, time=2015-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1772925, encodeId=8f521e7292531, content=<a href='/topic/show?id=89f3e742947' target=_blank style='color:#2F92EE;'>#纳米粒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77429, encryptionId=89f3e742947, topicName=纳米粒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8ae38449394, createdName=zjubiostat, createdTime=Mon Jun 22 13:04:00 CST 2015, time=2015-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18332, encodeId=302e18332e1, content=不知道其他肿瘤是否也能利用相似的机理制作出相应的纳米材料, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f12104305, createdName=hjj0000, createdTime=Sun Mar 15 09:20:00 CST 2015, time=2015-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279082, encodeId=e2f012e9082b0, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Wed Mar 11 01:04:00 CST 2015, time=2015-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405672, encodeId=498814056e2d0, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Wed Mar 11 01:04:00 CST 2015, time=2015-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425809, encodeId=ff451425809c0, content=<a href='/topic/show?id=a1e44e62210' target=_blank style='color:#2F92EE;'>#局部治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47622, encryptionId=a1e44e62210, topicName=局部治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1d3994789, createdName=venlin, createdTime=Wed Mar 11 01:04:00 CST 2015, time=2015-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580608, encodeId=93bf1580608d0, content=<a href='/topic/show?id=d4c6e7430be' target=_blank style='color:#2F92EE;'>#纳米粒子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77430, encryptionId=d4c6e7430be, topicName=纳米粒子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eedc16636878, createdName=ms920641618706883, createdTime=Wed Mar 11 01:04:00 CST 2015, time=2015-03-11, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=23771, encodeId=64f323e71ce, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sat May 16 20:03:00 CST 2015, time=2015-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1772925, encodeId=8f521e7292531, content=<a href='/topic/show?id=89f3e742947' target=_blank style='color:#2F92EE;'>#纳米粒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77429, encryptionId=89f3e742947, topicName=纳米粒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8ae38449394, createdName=zjubiostat, createdTime=Mon Jun 22 13:04:00 CST 2015, time=2015-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18332, encodeId=302e18332e1, content=不知道其他肿瘤是否也能利用相似的机理制作出相应的纳米材料, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f12104305, createdName=hjj0000, createdTime=Sun Mar 15 09:20:00 CST 2015, time=2015-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279082, encodeId=e2f012e9082b0, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Wed Mar 11 01:04:00 CST 2015, time=2015-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405672, encodeId=498814056e2d0, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Wed Mar 11 01:04:00 CST 2015, time=2015-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425809, encodeId=ff451425809c0, content=<a href='/topic/show?id=a1e44e62210' target=_blank style='color:#2F92EE;'>#局部治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47622, encryptionId=a1e44e62210, topicName=局部治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1d3994789, createdName=venlin, createdTime=Wed Mar 11 01:04:00 CST 2015, time=2015-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580608, encodeId=93bf1580608d0, content=<a href='/topic/show?id=d4c6e7430be' target=_blank style='color:#2F92EE;'>#纳米粒子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77430, encryptionId=d4c6e7430be, topicName=纳米粒子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eedc16636878, createdName=ms920641618706883, createdTime=Wed Mar 11 01:04:00 CST 2015, time=2015-03-11, status=1, ipAttribution=)]

相关资讯

FDA接受施贵宝PD-1抑制剂Opdivo治疗肺癌上市申请,免疫疗法进入主流实体瘤

今天施贵宝宣布FDA已接受其PD-1抑制剂Opdivo(通用名nivolumab)作为三线药物治疗鳞状非小细胞肺癌的上市申请,PDUFA日期定为今年6月22日。这标志着免疫疗法已经开始进入主流实体瘤的治疗。肺癌是癌症患者的最大杀手之一,85%的肺癌为非小细胞类型,其中25-30%为鳞状非小细胞肺癌。 PD-1抑制剂是当今竞争最为激烈的新药项目,其进展速度之快、覆盖范围之广都是史无前例的。哨卡

免疫疗法治疗肺癌的十点临床收获

在2014年芝加哥胸部癌症研讨会上,耶鲁大学癌症中心主任Roy S. Herbst医生总结了免疫疗法在肺癌治疗中的临床收获。Herbst所指的肿瘤免疫疗法还是限于免疫哨卡抑制抗体:抗PD-1抗体和抗CTLA 4抗体。目前,这类抗体仅获FDA批准治疗晚期黑色素瘤,上周施贵宝宣布美国FDA接受了其抗PD-1单抗Opdivo的sBLA并授予优先评审地位,PDUFA日期定为今年6月22日。Herbst博士

《原发性肺癌诊疗规范》更新内容(2015)

近几年,世界范围内原发性肺癌的内科治疗又有了迅猛的发展。更多肺癌驱动基因被发现和了解,使得肺癌患者在治疗前不仅要明确组织病理类型,还要明确分子病理类型。ALK融合基因及相应靶向治疗药物克唑替尼这片“新大陆”的发现,使我们对EGFR分子靶向治疗的理解又加深了一个层次。培美曲塞对于非鳞癌患者的疗效给大部分非小细胞肺癌(NSCLC">NSCLC)患者带来好消息,在分子靶向治疗时代,化疗的地位依

Respirology:胸腔积液肺癌患者的临床特征和存活率

背景和目的:胸腔积液肺癌的临床意义很少进行系统性的梳理。本研究的目的是确定肺癌合并胸腔积液患者的患病率,病因和自然历史,以及对他们生存的影响。方法:在我们机构中,对新诊断的超过4年的556例肺癌患者的影像学和临床资料进行回顾分析。结果:肺癌患者包括490例非小细胞肺癌和66例小细胞类型的肺癌。约40%的肺癌患者在他们的疾病过程中伴有胸腔积液。有一半的患者胸腔积液太小可吸取掉。这些积液没有发展到需要

欧美研究:PM2.5污染与肺癌关系密切

每年,全球大约有140万肺癌案例,已在过去的二十多年里成为世界上最常见的癌症。人们已经知道,吸烟和职业性暴露会导致肺癌患者增加。然而,在中国的一些大城市里,尽管吸烟的人数下降,健康和工作场所的安全状况已经得到改善。但仍能观察到肺癌的上升趋势。 美国和中国的学者将对pm2.5的污染和对肺癌的风险研究发表在英文期刊2014年6月Journal of Environmental Protection(

Ann Intern Med:低剂量CT扫描采用Lung-RADS标准识别肺癌无优势

低剂量CT(LDCT)扫描适用于肺癌的筛查已经被广受推荐,这主要源于美国国立胸部摄像研究(the National Lung Screening Trial,NLST)证据所支持。最近美国放射学会(American College of Radiology)发布了Lung-RADS标准(Lung-RADS是一种专门针对LDCT的肺癌扫描结果的分级和分类工具)。 为评估Lung-RADS相对于NLS